Direct and indirect costs of end-stage renal disease patients in the first and second years after initiation of nocturnal home haemodialysis, hospital haemodialysis and peritoneal dialysis

Purpose. To estimate the direct and indirect costs of end-stage renal disease (ESRD) patients in the first and second years of initiating peritoneal dialysis (PD), hospital-based haemodialysis (HD) and nocturnal home HD. Methods. A cost analysis was performed to estimate the annual costs of PD, hospital-based HD and nocturnal home HD for ESRD patients from both the health service provider's and societal perspectives. Empirical data on healthcare resource use, patients' out-of-pocket costs, time spent on transportation and dialysis by ESRD patients and time spent by caregivers were analysed. All costs were expressed in Hong Kong year 2017 dollars. Results. Analysis was based on 402 ESRD patients on maintenance dialysis (PD: 189; hospital-based HD: 170; and nocturnal home HD: 43). From the perspective of the healthcare provider, hospital-based HD had the highest total annual direct medical costs in the initial year (mean +/- SD) (hospital-based HD = $400 057 +/- 62 822; PD = $118 467 +/- 15 559; nocturnal home HD = $223 358 +/- 18 055; P< 0.001) and second year (hospital-based HD = $360 924 +/- 63 014; PD = $80 796 +/- 15 820; nocturnal home HD = $87 028 +/- 9059; P< 0.001). From the societal perspective, hospital-based HD had the highest total annual costs in the initial year (hospital-based HD = $452 151 +/- 73 327; PD = $189 191 +/- 61 735; nocturnal home HD = $242 038 +/- 28 281; P< 0.001) and second year (hospital-based HD = $413 017 +/- 73 501; PD = $151 520 +/- 60 353; nocturnal home HD = $105 708 +/- 23 853; P< 0.001). Conclusions. This study quantified the economic burden of ESRD patients, and assessed the annual healthcare and societal costs in the initial and second years of PD, hospital-based HD and nocturnal home HD in Hong Kong. From both perspectives, PD is cost-saving relative to hospital-based HD and nocturnal home HD, except that nocturnal home HD has the lowest cost in the second year of treatment from the societal perspective. Results from this cost analysis facilitate economic evaluation in Hong Kong for health services and management targeted at ESRD patients.